FDAsafety guidance95% confidence
ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Zydus Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Not specified
- Sub-indication
- General
Related signal: FDA Submission Update for ANDA220724 by Zydus Pharmaceuticals